Persist AI and Nivagen to Partner on AI-Driven Manufacturing Process

CIOTechOutlook Team | Tuesday, 13 August 2024, 02:47 IST

  • No Image
Persist AI and Nivagen have revealed a partnership to jointly create an advanced production method for long-acting injectable (LAI) medications, utilizing Persist's AI-driven formulation technology and Nivagen's manufacturing expertise. The partnership is focused on streamlining and speeding up the process of developing and approving LAI drugs, which offer consistent and extended drug release for weeks or months, enhancing patient compliance and results.
 
"We are excited to partner with Nivagen, a leading Pharmaceutical company with extensive experience and expertise in manufacturing and distributing pharmaceutical products. Together, we will leverage our AI-driven formulation platform to create a novel and scalable manufacturing process for long-acting injectables, which have the potential to transform the treatment of chronic diseases and improve patient quality of life," said Karthik Raman, CEO of Persist AI.
 
"We are delighted to collaborate with Persist AI, a pioneer in AI-based formulation development for drug delivery systems. Our Sacramento, CA facility is equipped with robotic lines using Isolator technology to produce sterile drug products in IV bags (both aseptically and terminally sterilized), vials, syringes, and cartridges.  Persist's new technology will enhance our capabilities to handle complex injectables like long-acting injectables at our new manufacturing site. We believe that their technology can significantly reduce the time and cost of developing and producing long-acting injectables, which are a growing and underserved market. We look forward to combining our manufacturing capabilities and distribution network with their innovative technology to bring a new and differentiated product to market," said Jay Shukla, CEO of Nivagen.
🍪 Do you like cookies?

We use cookies to ensure you get the best experience on our website. Read more...